GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) — NexImmune, Inc. NEXI (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors…Read More
NexImmune Announces 1for25 Reverse Stock Split NexImmune NASDAQNEXI
